Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...
Researchers will join a new NIH-supported network working to develop novel approach methodologies that complement or replace ...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc. (HKEX:1228), a China and US-based global biopharmaceutical company committed to the research, development and ...
REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...
Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results